@article {Noyan2020.06.22.20137570, author = {Mehmet Alican Noyan and Murat Durdu and Ali Haydar Eskiocak}, title = {TzanckNet: A convolutional neural network to identify cells in the cytology of erosive-vesiculobullous diseases}, elocation-id = {2020.06.22.20137570}, year = {2020}, doi = {10.1101/2020.06.22.20137570}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Tzanck smear test is a low-cost, rapid and reliable tool which can be used for the diagnosis of many erosive-vesiculobullous, tumoral and granulomatous diseases. Currently its use is limited mainly due to lack of experience in interpretation of the smears. We developed a deep learning model, TzanckNet, that can identify cells in Tzanck smear test findings. TzanckNet was trained on a retrospective development dataset of 2260 Tzanck smear images collected between December 2006 {\textendash} December 2019. The finalized model was evaluated using a prospective validation dataset of 359 Tzanck smear images collected from 15 patients during January 2020. It is designed to recognize six cell types (acantholytic cells, eosinophils, hypha, multinucleated giant cells, normal keratinocytes and tadpole cells). For 359 images and 6 cell types, TzanckNet made 2154 predictions. The accuracy was 94.3 \% (95\% CI 93.4 to 95.3), the sensitivity was 83.7 \% (95\% CI 80.3 to 87.0) and the specificity was 97.3 \% (95\% CI 96.5 to 98.1). The area under the receiver operating characteristic curve was 0.974. Our results show that TzanckNet has the potential to lower the experience barrier needed to use this test, broadening its user base, and hence improving patient well-being.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Ba{\c s}kent University Institutional Review Board (Project no: KA19/401).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and analyzed during the study are not currently publicly available.}, URL = {https://www.medrxiv.org/content/early/2020/06/23/2020.06.22.20137570}, eprint = {https://www.medrxiv.org/content/early/2020/06/23/2020.06.22.20137570.full.pdf}, journal = {medRxiv} }